Abstract
The plant-based secretolytic Sunipran, used in the comprehensive treatment of upper respiratory tract diseases, promotes faster recovery without causing adverse side effects. The drug effectively regulates secretion and normalizes mucus viscosity, eliminates mucostasis, and restores mucociliary clearance. The reduction in mucus viscosity is achieved by stimulating the secretory cells of the upper respiratory tract mucosa, which produce neutral mucopolysaccharides. In addition to its secretolytic effect, Sunipran exhibits anti-inflammatory, antiviral, and immunomodulatory properties.